

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number  
**WO 2005/068466 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 487/04**,  
A61K 31/5517, A61P 25/00

(21) International Application Number:  
PCT/IB2005/000263

(22) International Filing Date: 5 January 2005 (05.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0400700.1 13 January 2004 (13.01.2004) GB  
60/544,866 13 February 2004 (13.02.2004) US

(71) Applicant (for GB only): **PFIZER LIMITED** [GB/GB];  
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant (for all designated States except GB, US):  
**PFIZER INC.** [US/US]; 235 East 42nd Street, New York,  
NY 10017 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **RYCKMANS,**  
Thomas [BE/GB]; Pfizer Global Research and Develop-  
ment, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: **WOOD, David, J.** et al.; Pfizer Research and  
Development, Ramsgate Road, Sandwich, Kent CT13 9NJ  
(GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GI,  
GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS USEFUL IN THERAPY



(57) Abstract: Compounds of formula (I), or a pharmaceutically ac-  
ceptable derivative thereof, wherein: X represents NR or O; R repre-  
sents hydrogen, C<sub>1-8</sub> alkyl or SO<sub>2</sub>[C<sub>1-8</sub> alkyl]; W represents N or CH;  
Y and Y' independently represent hydrogen, halogen, OII, CF<sub>3</sub>, OCF<sub>3</sub>,  
CN, NH<sub>2</sub> C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkyloxy or C<sub>3-8</sub> cycloalkyl; Ring A represents  
a heterocyclic ring containing at least one nitrogen atom; Z represents a  
direct link, C<sub>1-8</sub> alkyl or C<sub>3-8</sub> cycloalkyl; R<sup>1</sup> represents R<sup>2</sup>, OR<sup>2</sup>, OR<sup>3</sup>, R<sup>4</sup>,  
N(R<sup>2</sup>)[C<sub>1-8</sub> alkylene]<sub>n</sub>, R<sup>4</sup>, NCOR<sup>2</sup>, or SR<sup>4</sup>; R<sup>2</sup> and R<sup>4</sup> independently rep-  
resent hydrogen, C<sub>3-8</sub> cycloalkyl, CF<sub>3</sub>, Ar or Het; R<sup>3</sup> represents a direct  
link or C<sub>1-8</sub> alkyl; is 0 or 1; Ar represents an aromatic ring, optionally

fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below; Het represents a hetero-  
cyclic ring optionally substituted with one or more groups as described below, and/or optionally fused to an aromatic ring which  
is optionally substituted with one or more groups as described below; at each occurrence C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkylene and C<sub>3-8</sub> cycloalkyl  
may be independently optionally substituted with one or more groups as described below; substituent groups for Ar, Het, C<sub>1-8</sub> alkyl,  
C<sub>1-8</sub> alkylene and C<sub>3-8</sub> cycloalkyl referred to the above are independently selected from hydrogen, halogen, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkyloxy,  
S[C<sub>1-8</sub> alkyl], CN, CF<sub>3</sub>, NH<sub>2</sub> and OH; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hy-  
pertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion  
sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preeclampsia, premature  
ejaculation, premature (preterm) labor and Raynaud's disease.